{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:49:34Z","timestamp":1755218974483,"version":"3.43.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Tuberculosis (TB) is now understood to exist on a spectrum from TB infection to active TB disease. While World Health Organization guidelines target TB infection and TB disease, they overlook individuals with early TB in the middle of this spectrum.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate chest radiograph (CR)\u2013guided screening strategies among household contacts (HHCs) of patients with TB in a high-burden setting.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This decision analytical model was constructed from June 1 to November 31, 2024. Community-based care in an environment with high TB burden and limited resources was used as the setting in Lima, Peru. Participants included a hypothetical cohort of 1000 HHCs with positive results of a tuberculin skin test and negative results of a sputum culture who were cleared of TB disease based on a clinician\u2019s evaluation. The hypothetical cohort was based on the clinical and demographic features of a cohort studied between September 1, 2009, and August 29, 2012.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Strategy 1 included CR screening to rule out TB disease followed by TB preventive therapy for all; strategy 2, CR screening with treatment for TB disease for those with abnormal CR findings and TB preventive therapy for those without; and strategy 3, observation without pharmacological intervention. We modeled 6 intervention scenarios by applying strategies 1 and 2 to the entire HHC population, to HHCs younger than 35 years, and to HHCs younger than 19 years (Peru\u2019s national TB policy).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>TB cases averted, serious adverse events (SAEs), and drug resistance.<\/jats:p><\/jats:sec>Results<\/jats:title>A simulated cohort of 1000 HHCs with age and clinical status distributions was based on a previously published cohort of 12\u202f767 TB HHCs in Lima, Peru. Of these, 7661 (60.0%) were male, 4212 (33.0%) were younger than 15 years, and 444 (3.4%) developed TB during 1 year of follow-up. Strategy 2 applied to all HHCs reduced TB cases by 71% to 81%, outperforming strategy 1 applied to all HHCs, which reduced cases by 49% to 69%. Strategy 2 reduced acquired isoniazid resistance but increased SAEs. When both strategies were restricted to HHCs younger than 19 years, strategy 2 reduced TB cases by 42% to 50%. Expanding treatment to older adults further reduced cases but also increased SAEs (19-22 additional SAEs).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this model of TB HHC management, CR-guided identification and treatment of early TB was more effective than universal isoniazid preventive therapy, especially in children and young adults. Trade-offs between benefit and harm must be carefully considered in older adults.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.25207","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T15:00:31Z","timestamp":1754492431000},"page":"e2525207","source":"Crossref","is-referenced-by-count":0,"title":["Integrating Early Tuberculosis States Into Contact Management in Peru"],"prefix":"10.1001","volume":"8","author":[{"given":"Qi","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan-Chin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Global Health Equity, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Madden","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan B.","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Global Health Equity, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"issue":"6","key":"zoi250712r2","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/infdis\/jiy265","article-title":"Risk and timing of tuberculosis among close contacts of persons with infectious tuberculosis.","volume":"218","author":"Reichler","year":"2018","journal-title":"J Infect Dis"},{"key":"zoi250712r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101047","article-title":"Population-wide active case finding as a strategy to end TB.","volume":"46","author":"Nguyen","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"issue":"12","key":"zoi250712r4","doi-asserted-by":"publisher","first-page":"e1260","DOI":"10.1016\/S2214-109X(18)30449-2","article-title":"Preventing tuberculosis in household contacts crucial to protect children and contain epidemic spread.","volume":"6","author":"Marais","year":"2018","journal-title":"Lancet Glob Health"},{"issue":"2","key":"zoi250712r8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1164\/rccm.202006-2394PP","article-title":"The epidemiological importance of subclinical tuberculosis: a critical reappraisal.","volume":"203","author":"Kendall","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"zoi250712r9","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3201\/eid1205.050681","article-title":"Isoniazid preventive therapy and risk for resistant tuberculosis.","volume":"12","author":"Balcells","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"zoi250712r11","doi-asserted-by":"publisher","DOI":"10.1177\/20503121241233232","article-title":"Facilitators and barriers to implementing chest radiography in tuberculosis systematic screening of clinically high-risk groups in Ethiopia: a qualitative study.","author":"Abraham","year":"2024","journal-title":"SAGE Open Med"},{"issue":"Suppl 4","key":"zoi250712r12","doi-asserted-by":"publisher","first-page":"S1179","DOI":"10.1093\/infdis\/jir451","article-title":"Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response.","volume":"204","author":"Achkar","year":"2011","journal-title":"J Infect Dis"},{"issue":"4","key":"zoi250712r13","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00021-18","article-title":"Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection.","volume":"31","author":"Drain","year":"2018","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"zoi250712r14","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S2213-2600(24)00028-6","article-title":"Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise.","volume":"12","author":"Coussens","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"6","key":"zoi250712r16","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(23)00153-2","article-title":"The unsustainable anachronism of tuberculosis diagnosis.","volume":"4","author":"The Lancet Microbe","year":"2023","journal-title":"Lancet Microbe"},{"issue":"7","key":"zoi250712r17","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1164\/rccm.202202-0259OC","article-title":"The contribution of chest radiography to the clinical management of children exposed to tuberculosis.","volume":"206","author":"Huang","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"zoi250712r18","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3201\/eid3006.231699","article-title":"Chest radiograph screening for detecting subclinical tuberculosis in asymptomatic household contacts, Peru.","volume":"30","author":"Tan","year":"2024","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"zoi250712r20","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S2213-2600(23)00085-1","article-title":"Do chest x-ray-positive, sputum-negative individuals warrant more attention during tuberculosis screening?","volume":"11","author":"Kendall","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"1","key":"zoi250712r21","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s12889-023-15197-7","article-title":"Tuberculosis in older adults: case studies from four countries with rapidly ageing populations in the western pacific region.","volume":"23","author":"Teo","year":"2023","journal-title":"BMC Public Health"},{"key":"zoi250712r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100770","article-title":"Tuberculosis in older adults: challenges and best practices in the Western Pacific Region.","volume":"36","author":"Teo","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"2","key":"zoi250712r23","article-title":"Isoniazid for preventing tuberculosis in non-HIV infected persons.","volume":"1999","author":"Smieja","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"zoi250712r26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/cid\/ciad246","article-title":"A systematic review and meta-analysis of tuberculous preventative therapy adverse events.","volume":"77","author":"Melnychuk","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"9","key":"zoi250712r27","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(23)00096-6","article-title":"Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.","volume":"11","author":"Winters","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"5","key":"zoi250712r28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults.","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"zoi250712r29","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection.","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250712r30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(19)30575-4","article-title":"Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.","volume":"20","author":"Campbell","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"zoi250712r31","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2104535","article-title":"Shorter treatment for nonsevere tuberculosis in African and Indian children.","volume":"386","author":"Turkova","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi250712r33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M17-0609","article-title":"Treatment of latent tuberculosis infection: an updated network meta-analysis.","volume":"167","author":"Zenner","year":"2017","journal-title":"Ann Intern Med"},{"issue":"11","key":"zoi250712r34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293535","article-title":"Treatment for radiographically active, sputum culture-negative pulmonary tuberculosis: a systematic review and meta-analysis.","volume":"18","author":"Gray","year":"2023","journal-title":"PLoS One"},{"issue":"18","key":"zoi250712r35","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis.","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250712r36","doi-asserted-by":"publisher","first-page":"452","DOI":"10.4103\/jfmpc.jfmpc_1331_22","article-title":"Treatment outcomes and associated factors among patients with drug-sensitive tuberculosis on daily fixed-dose combination drugs: a cohort study from Ahmedabad, India.","volume":"12","author":"Prajapati","year":"2023","journal-title":"J Family Med Prim Care"},{"issue":"11","key":"zoi250712r37","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"zoi250712r38","first-page":"278","article-title":"National surveillance of resistance to antituberculosis drugs, Peru 2005-2006. Article in Spanish.","volume":"26","author":"Asencios","year":"2009","journal-title":"Rev Peru Med Exp Salud Publica"},{"issue":"5","key":"zoi250712r39","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1714284","article-title":"Safety and side effects of rifampin versus isoniazid in children.","volume":"379","author":"Diallo","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi250712r40","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1093\/cid\/ciw126","article-title":"Factors associated with noncompletion of latent tuberculosis infection treatment: experience from the PREVENT TB trial in the United States and Canada.","volume":"62","author":"Moro","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"24","key":"zoi250712r42","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.3390\/jcm10245888","article-title":"Tuberculosis in the elderly.","volume":"10","author":"Caraux-Paz","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"zoi250712r43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40249-017-0284-4","article-title":"The strategic framework of tuberculosis control and prevention in the elderly: a scoping review towards End TB targets.","volume":"6","author":"Li","year":"2017","journal-title":"Infect Dis Poverty"},{"issue":"12","key":"zoi250712r44","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024286","article-title":"Factors affecting the acceptability of isoniazid preventive therapy among healthcare providers in selected HIV clinics in Nairobi County, Kenya: a qualitative study.","volume":"8","author":"Wambiya","year":"2018","journal-title":"BMJ Open"},{"issue":"3","key":"zoi250712r45","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/tmi.13350","article-title":"Contact evaluation and isoniazid preventive therapy among close and household contacts of tuberculosis patients in Lima, Peru: an analysis of routine data.","volume":"25","author":"Otero","year":"2020","journal-title":"Trop Med Int Health"},{"issue":"12","key":"zoi250712r46","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/aje\/kwx025","article-title":"Transmission of Mycobacterium tuberculosis in households and the community: a systematic review and meta-analysis.","volume":"185","author":"Martinez","year":"2017","journal-title":"Am J Epidemiol"},{"key":"zoi250712r1","unstructured":"World Health Organization. Global tuberculosis report 2024. November 5, 2024. Accessed January 8, 2025. https:\/\/iris.who.int\/bitstream\/handle\/10665\/379339\/9789240101531-eng.pdf?sequence=1"},{"key":"zoi250712r5","unstructured":"World Health Organization. Implementing the end TB strategy: the essentials. Accessed March 6, 2023. https:\/\/www.who.int\/publications\/i\/item\/WHO-HTM-TB-2015.19"},{"key":"zoi250712r6","unstructured":"World Health Organization Guidelines on the management of latent tuberculosis infection. 2015. Accessed November 1, 2024. https:\/\/apps.who.int\/iris\/bitstream\/10665\/136471\/1\/9789241548908_eng.pdf"},{"key":"zoi250712r7","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 1: prevention\u2014tuberculosis preventive treatment. 2nd ed. 2024. Accessed November 1, 2024. https:\/\/iris.who.int\/bitstream\/handle\/10665\/378536\/9789240096196-eng.pdf?sequence=1"},{"key":"zoi250712r10","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 2: screening\u2014systematic screening for tuberculosis disease. 2021. Accessed November 1, 2024. https:\/\/iris.who.int\/bitstream\/handle\/10665\/340255\/9789240022676-eng.pdf?sequence=1"},{"key":"zoi250712r15","unstructured":"World Health Organization. Global tuberculosis report 2024: asymptomatic tuberculosis and implications for programmatic action. 2024. Accessed November 1, 2024. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024\/featured-topics\/asymptomatic-tb"},{"key":"zoi250712r19","unstructured":"World Health Organization. Global tuberculosis report 2021. 2021. Accessed November 1, 2024. https:\/\/iris.who.int\/bitstream\/handle\/10665\/346387\/9789240037021-eng.pdf?sequence=1"},{"key":"zoi250712r24","unstructured":"Ministry of Health Peru. General Directorate of People\u2019s Health\u2014national health prevention strategy and technical health standard for the control of tuberculosis. Article in Spanish. 2006. Accessed March 7, 2023. http:\/\/bvs.minsa.gob.pe\/local\/MINSA\/3731.pdf"},{"key":"zoi250712r25","unstructured":"National Cancer Institute. Patient-reported outcomes version of the Common Terminology Criteria for Adverse Events. Updated June 5, 2025. Accessed November 1, 2024. https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae"},{"key":"zoi250712r32","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment\u2014drug-susceptible tuberculosis treatment. 2022. Accessed November 1, 2024. https:\/\/iris.who.int\/bitstream\/handle\/10665\/353829\/9789240048126-eng.pdf?sequence=1"},{"key":"zoi250712r41","unstructured":"World Health Organization Department of HIV\/AIDS. Stop TB Department. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. 2011. Accessed November 1, 2024. https:\/\/iris.who.int\/bitstream\/handle\/10665\/44472\/9789241500708_eng.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2837322\/tan_2025_oi_250712_1753891362.68661.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T15:00:35Z","timestamp":1754492435000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2837322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.25207","relation":{},"ISSN":["2574-3805"],"issn-type":[{"type":"electronic","value":"2574-3805"}],"subject":[],"published":{"date-parts":[[2025,8,6]]}}}